No Data
No Data
HC Wainwright & Co. Reiterates Buy on Bionomics, Maintains $8 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.
Buy Rating Affirmed on Bionomics as BNC210 Enters Critical Phase 3 Trial for Social Anxiety Disorder
Trending Stocks Today | Onconetix Soars 35.1% Pre-Market
July 18th - US stocks trending pre-market: Gainers: $Onconetix(ONCO.US)$ soars 35.1% to $0.2 with a turnover of $8.74 million. $Siyata Mobile(SYTA.US)$ surges 44.92% to $0.99 with a turnover of $17.1
Express News | Bionomics Has Initiated Patient Screening For The Phase 3 AFFIRM-1 Trial Evaluating The Safety And Efficacy Of BNC210 For The Acute, As-needed Treatment Of Social Anxiety Disorder, Topline Results Are Expected In Q3 2025
Express News | Bionomics Ltd - Affirm-1 to Enroll 330 Adult Patients With Sad
Express News | Bionomics Ltd - Topline Results Are Expected in Q3 2025
No Data